Eva Wesley

Novartis plans to sell Morphosys' business, acquired for €2.7 billion in 2023, affecting 330 employees as it closes two factories by 2025.

Grifols faced a turbulent 2024 with leadership changes, legal battles, and debt refinancing. Accusations by Gotham City Research and a rejected takeover bid from Brookfield added pressure. Despite setbacks, the company focused on restructuring, selling assets, and extending debt maturity to 2030. Grifols now aims to stabilize operations while managing ongoing challenges and market expectations.

Zerintia HealthTech, a Spanish digital health firm, expands into Saudi Arabia and the UAE with its 4RemoteHealth platform, enabling real-time remote collaboration in complex medical settings. Partnering with El-Ajou and Emitac Healthcare Solutions, the company aims to lead digital health globally. Founded in 2022, Zerintia integrates IoT, wearables, and augmented reality into healthcare solutions.

In 2024, Spanish pharma focused on stabilizing finances rather than expanding, with six major players seeing an 18% profit drop compared to 2023. While Faes Farma and PharmaMar maintained steady growth, Grifols, Almirall, and Rovi struggled with significant declines. The sector enters 2025 aiming to boost profitability amid mixed financial performance.

Global markets saw mixed performances: DAX fell 0.6% to 19,909 points, pressured by BASF, BMW, and Bayer. MDAX and TecDAX also dropped. Hang Seng gained 0.7%, while CSI 300 lost 1.2%. In the U.S., Dow rose 0.6%, NASDAQ climbed 1.5%. Biotech shares gained, with Vertex Pharma up 1.3% and Arrowhead Pharma surging 2.3%. 0 SHARES

German biotech financing surged 78% in 2024, totalling €1.92 billion, driven by venture capital (€898 million), public market funding (€999 million), and an IPO. Notable deals included Qiagen’s €400 million convertible bond and major rounds from Tubulis, ITM, SciRhom, and Infinite Roots. Venture capital growth reflects larger investment sizes rather than more financing rounds. 0 SHARES

The biotech industry thrived during the pandemic, fueled by vaccine demand, but post-2022 saw capital declines. In 2024, capital increases reached €999 million, led by Qiagen and Immatics. Cancer therapies dominate research and venture funding, with ITM, Catalym, and Tubulis raising significant investments. Emerging sectors like foodtech are gaining traction, highlighting biotech’s innovation-driven potential.

Grifols secured a $21 million grant from the Michael J. Fox Foundation to study plasma biomarkers for early Parkinson’s detection. The 10-year Chronos PD project will analyze longitudinal plasma samples, potentially revolutionizing diagnosis and therapies. Early detection is critical, as current methods often diagnose too late for intervention. Grifols’ plasma expertise enhances research possibilities. 0 SHARES

For AseBio, it's important that the deployment of the Strategic Plan allows for the articulation of the environment the biotech requires to develop

HM Ciocc leads cancer research in Madrid's private sector, with 144 trials recruiting and 374 active studies in 2024.